A positive correlation between stearoyl-CoA desaturase 1 expression and metabolic diseases has been reported in rodent and human. These findings indicate that SCD1 is a promising therapeutic target for the chronic treatment of diabetes and dyslipidemia. The SCD1 enzyme is expressed at high levels in several human tissues and is required for the biosynthesis of monounsaturated fatty acids which are involved in many biological processes. Liver-targeted SCD inhibitors were designed to pharmacologically manipulate SCD1 activity in the liver to avoid adverse events due to systemic inhibition. This paper describes the development of a plasma-based SCD assay to assess the level of SCD inhibition, which is defined in this manuscript as target engagement. Essentially, animals are dosed with an exogenous deuterated tracer (d7-stearic acid) as substrate and the converted d7-oleic acid product is measured to monitor SCD1 inhibition. This study reveals that this plasma-based assay correlates with liver SCD1 inhibition and can thus have clinical utility.
Introduction
Obesity is quickly approaching epidemic levels in developed countries mainly because of the reduction of physical activity and the increased consumption of processed foods that are rich in carbohydrate and fat. Obesity is believed to be a major triggering factor for the development of metabolic disorders, such as type-2 diabetes (1) . An association has been demonstrated between alterations in lipid homeostasis and the onset and severity of these diseases (2, 3) . Thus, significant efforts are being made toward effective treatment and prevention of these conditions. Stearoyl-CoA desaturase 1 (SCD1) is an enzyme that catalyzes the biosynthesis of monounsaturated fatty acids from saturated fatty acids that are either synthesized de novo or derived from diet. SCD1 is responsible for the formation of a cis-double bond at the Δ9-position of palmitoyl-and stearoyl-CoA to generate palmitoleic and oleic acids, the main substrates in triglycerides, cholesterol esters, and phospholipids ( Fig. 1 
) (4).
Interestingly, SCD1 activity can be measured from the ratio of SCD1 products over substrates. In the literature, this ratio is generally referred as the desaturation index (3) .
There are four mouse SCD isoforms (SCD1, SCD2, SCD3, and SCD4), two rat (SCD1 and SCD2), and two human (SCD1 and SCD5) (4, 5) . Although SCD1 is ubiquitously expressed, it is predominant in liver and adipose tissues. These tissues are the principal sites of de novo lipogenesis as they have a high capacity to convert carbohydrate into fatty acids when glycolytic and lipogenic enzymes are induced and activated. Targeted deletion of the SCD1 gene in mice has shown that this enzyme is important for lipid by guest, on October 22, 2017 www.jlr.org Downloaded from homeostasis and body weight regulation (6) . Thus, it is postulated that the inhibition of SCD1 should reduce lipid synthesis and storage which would be beneficial for the treatment of diabetes and dyslipidemia.
We previously reported that inhibition of SCD in skin and eye leads to adverse events consisting of dry eye, squinting, and alopecia. These adverse events are observed when systemic SCD inhibitors are used and are believed to be mechanism-based due to depletion of essential SCD-derived lubricating lipids. In order to achieve a therapeutic window for SCD inhibition, a liver-targeting strategy was employed to target the SCD inhibitor to the organ believed to be responsible for the therapeutic efficacy (liver) while minimizing its exposure in the tissues (skin and eye) associated with adverse events (7) (8) (9) (10) . The goal was achieved by designing MK-8245, a liver-targeted SCD inhibitor believed to inhibit the SCD enzyme solely in the liver and not in other tissues for the following reasons. When SCD inhibition has been measured by desaturation index in tissues of rodents treated with MK-8245, the desaturation index was significantly reduced in liver but not in other tissues such as skin, eye and adipose tissue (7) . This inhibition of desaturation index is a direct measure of SCD inhibition. While we have not specifically measured SCD inhibition in tissues other than fat, skin, eye and liver, we have demonstrated that there is a good correlation between the inhibitor concentration and the inhibition of SCD in tissues. We have measured the concentration of livertargeted SCD inhibitors such as MK-8245 in tissues other than liver, skin and eye and have found that the levels are indeed very low. For example, the levels of MK-8245 in heart following a 10 mg/kg dose oral dose in mice is very low and comparable to the by guest, on October 22, 2017 www.jlr.org Downloaded from levels found in skin and eye where no SCD inhibition has been observed. The reason for these low levels in tissues other than liver is that MK-8245 and other liver-targeted SCD inhibitors have low cell penetration in combination with being substrates for the liverspecific organic anion transporting polypeptides (OATP) which are uptake transport proteins (7) . In order to confirm that levels of MK-8245 were low in all tissues (except liver), a quantitative whole body audioradiography (QWBA) was conducted where the concentration of 14 C-MK-8245 was quantified in all tissues (data not shown). As expected, levels were only significant in liver and the areas involved in excretion (i.e. levels of MK-8245 were high in stomach and intestine due to unabsorbed material being eliminated).
While it is feasible to measure liver target engagement in preclinical species (8) (9) (10) , it would be difficult to assess this clinically. Thus, in order to confirm target engagement of these liver-targeted compounds, we developed a biological assay using a deuteriumlabeled exogenous tracer to measure inhibition of SCD1 activity in plasma. Over the past decade, significant advances have been made in the measurement of lipids using stable 
Plasma d7-stearic acid & d7-oleic acid extraction and analysis
All plasma samples were kept at -80 o C and were thawed on ice just before processing them. A standard curve ranging from 0 to 25 μM was first prepared with d7-stearic acid (stock solution in dimethyl sulfoxide) and d7-oleic acid (stock solution in methanol) in blank SD rat plasma for quantification. The stock solution of d7-stearic acid is kept in dimethyl sulfoxide to prevent its precipitation over time. A total of 50 μl of plasma per sample, including the standard samples, was transferred to 2 ml square-well titer plates.
Plasma samples were hydrolyzed by adding 100 μl of 10N NaOH, containing 300 ng/ml of the internal standard 13 C-oleic acid, and by incubating 1 h at 65 o C in a thermomixer block.
Once cooled to room temperature, 200 μl of isooctane was added, the plate were sealed and submitted to a vigorous agitation for 15 min to perform the first extraction. The plates were then centrifuged to separate the isooctane layer from the aqueous lower phase and allowed to freeze at -80 o C for at least 3 h. Plates were then turned upside down to discard the isooctane containing the non-desirable lipids. While keeping the plates on dry ice, the surface of the aqueous phase was then washed with 100 μl isooctane. Again, the plates were turned upside down and the isooctane was discarded. The sample plates were μl. HPLC separation was achieved using a 300 μl/ml flow rate and by increasing from 10% B to 30% B in 0.2 min, then to 72% B in 1.8 min, then 73% B in 2 min, then 74% B in 3 min, then 78% B in 2 min, and finally reached 100% B after 1 min. After a total gradient of 10 min, the 100% B was held for 1 min to clean the column and equilibrated back to 10% B.
It was diverted from the mass spectrometer during the 0-3 min time period to the waste containers for a total acquisition time of 12 min. The mass spectrometer was operated in ESI negative mode. To minimize the plasma matrix interference, the isotope labeled fatty acids were analyzed using selective reaction monitoring (SRM) mode. Since these molecules have poor fragmentation efficiencies, the collision energy was kept as low as 15 and the transitions used were the following; d7-oleic acid 288. 
SCD inhibitor titration with d7-stearic acid
Animals were dosed orally with MK-8245 or vehicle (0.5% methocel) an hour prior to oral dosing with d7-stearic acid (5 mg/kg, 2 ml/kg). SD rats were dosed with deuteriumlabeled tracer at time 0 (T0). Plasma samples (100 μl) were collected from tail in anticoagulant EDTA at different time points.
d7-stearic acid and 14 C-stearic acid dual tracing study A dual tracing study was carried out to confirm that the inhibition of SCD1 in the liver with MK-8245, a liver-targeted SCD inhibitor, correlates with the measurements of inhibition in plasma.
Either vehicle (0.5% methocel) or the liver-targeted compound MK-8245 at 0.11, 0.33, or 2 mg/kg was orally administered to SD rats (1 ml/kg). An hour later, which corresponds to the T0, the animals received the d7-stearic acid tracer at 2.5 mg/ml as a nanocrystal dispersion (NCD) liquid formulation (2 ml/kg). It is well known in the literature that the absorption of stearic acid is less efficient than other saturated fatty acids (16, 17) . Using this type of formulation, we were able to considerably improve on the d7-stearic acid absorption (data not shown). The NCD of d7-stearic acid (50 mg/ml) was prepared by milling a coarse suspension of d7-stearic acid in an aqueous solution composed of 1.05% (w/v) hydroxypropyl cellulose, 0.2% sodium lauryl sulfate, and 5.25% glycine. Media milling was performed at 5°C using a NanoMill-01 and 0. layer was transferred to a 1.5 ml microcentrifuge tube. The organic layers were washed two times with saturated potassium chloride in water. Samples were mixed and centrifuged at 14000 rpm for 10 min at 4 ˚C to obtain a clear top organic/low water phase separation. The resulting organic layers were quantified on a reverse phase (C18) HPLC system equipped with a radioactivity detector to estimate the radiolabeled stearic acid and oleic acid products.
Duration of efficacy in rats by oral d7-stearic acid plasma-based assay
We evaluated the duration of MK-8245 target engagement in rats using the deuteriumlabeled stearic acid. SD rats were orally pre-dosed with the vehicle (methocel 0.5%) or an oral dose of 5 mg/kg of d7-stearic acid (2 ml/kg). Again, following administration of the tracer, 100 μl of plasma was collected in anti-coagulant EDTA at several time points for fatty acid extraction and analysis as described previously.
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Results & Discussion
The appropriate dosing of d7-stearic acid was key to establishing the SCD inhibition assay in plasma. While keeping the exogenous tracer as low as possible, to not disturb the endogeneous lipids, it is essential to have enough absorbed to measure its product d7-oleic acid. Figure 3 reveals the average responses for each dosing group. The conversion of the d7-stearic acid to d7-oleic acid shows good dose proportionality. The maximum d7-oleic acid product measured for each dose was at 4 h. The 5 mg/kg dose of d7-stearic acid was selected for the following studies as it showed favorable and measurable levels of d7-oleic acid.
d7-stearic acid and 14 C-stearic acid dual tracing study MK-8245 was designed to inhibit SCD1 activity specifically in the liver to improve the therapeutic window for treating diabetes and dyslipidemia without causing adverse events in tissues such as skin and eye since SCD1 is ubiquitously expressed and essential in other physiological processes. The main challenge was to demonstrate that we could inhibit SCD1 in the liver and correlate this inhibition in easily sampled biological fluid in animals that could be translated to human clinical studies. Figure 4A reveals that MK-8245 had no effect on the d7-stearic acid absorption as reflected by the amount of d7-stearic acid measured in the rat plasma over the course of the experiment. The results of the exogenous deuterium tracer showed a dose-dependant inhibitory effect from MK-8245 on the amount of d7-oleic acid measured over time and that 2 mg/kg of MK-8245 demonstrated near complete inhibition of d7-oleic acid formation (Fig. 4A ). This near complete inhibition further supports that the liver is the major organ responsible for d7-oleic acid formation observed in plasma since almost no noticeable background level from other organs can be detected after liver-specific inhibition with MK-8245. The plasma obtained at termination also reflected the inhibition in d7-oleic acid conversion in a dose-dependant fashion, as observed in Figure 4B . As shown in Figure 4C , we have found that there is no significant difference between the inhibition of the plasma d7-oleic acid/d7-stearic acid ratio and the liver 14 C-oleic acid/ 14 C-stearic acid ratio upon treatment with different doses of the SCD inhibitor MK-8245 in SD rats. A 100-fold difference was observed between the liver and the plasma radiolabeled oleate/stearate which is mainly due to liver absorption of the intravenous vs oral dosage of the labeled tracers.
The 14C-tracer was intentionally given via the intravenous route to ensure the passage of the tracer in the liver as its free acid form since it must be converted to stearate-CoA to be An interesting mandate was to evaluate the duration of inhibition of MK-8245 on the conversion of d7-stearic acid to d7-oleic acid. Figure 5A shows the levels of d7-stearic acid measured after oral dosage of tracer 1 h post dose of either vehicle or MK-8245.
Similar levels of d7-stearic acid were also measured in animals after oral dosage of tracer 6 and 17 h post dose of either vehicle or MK-8245 (data not shown). Figure 5B shows the complete inhibition of d7-oleic acid formation after 1 h pre-treatment with 10 mg/kg of MK-8245 when compared to vehicle-treated rats. Interestingly, the levels of d7-oleic acid measured in the vehicle treated animals in Figure 5B and 5C are different. This difference is mainly a reflection of the feeding state. Figure 5C shows lower levels of d7-oleic acid because the tracer is dosed later in the day when the rats are not eating and hence have lower SCD1 activity. Even with a decreased SCD1 activity, the levels of d7-oleic acid measured in Figure 5C still show a significant reduction in d7-oleic acid 
